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Abstract 
 
Background. To assess the within trial cost-effectiveness of an NHS ovarian cancer 
screening (OCS) programme using data from UKCTOCS and extrapolate results 
based on average life expectancy. 
Methods. Within trial economic evaluation of no screening (C) versus either (1) an 
annual OCS programme using transvaginal ultrasound (USS) or (2) an annual ovarian 
cancer multimodal screening programme with serum CA125 interpreted using a risk 
algorithm (ROCA) and transvaginal ultrasound as a second line test (MMS), plus 
comparison of lifetime extrapolation of the no screening arm and the MMS 
programme using both a predictive and a Markov model. 
Results. Using a CA125-ROCA cost of £20, the within trial results show USS to be 
strictly dominated by MMS, with the MMS versus C comparison returning an 
Incremental Cost-Effectiveness ratio (ICER) of £91,452 per life year gained (LYG). If 
the CA125-ROCA unit cost is reduced to £15 the ICER becomes £77,818 per LYG. 
Predictive extrapolation over the expected lifetime of the UKCTOCS women returns 
an ICER of £30,033 per LYG, while Markov modelling produces an ICER of £46,922 
per QALY. 
Conclusions Analysis suggests that, after accounting for the lead-time required to 
establish full mortality benefits, a national OCS programme based on the MMS 
strategy quickly approaches the current NICE thresholds for cost-effectiveness when 
extrapolated out to lifetime as compared to the within trial ICER estimates. Whether 
MMS could be recommended on economic grounds would depend on the 
confirmation and size of the mortality benefit at the end of an ongoing follow-up of 
the UKCTOCS cohort. 
 
Key words: Ovarian cancer screening, UKCTOCS, cost-effectiveness, randomised 
controlled trial, CA125, TVS. 
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Introduction 
 
Ovarian cancer is the sixth most common cancer in women with approximately 7,300 
new cases diagnosed in the UK in 2013 (Cancer Research, 2016). Since the late 
1970s, incidence has increased by almost 15%. It remains the fifth most common 
cause of cancer death in woman and the most common cause of gynaecological 
cancer death. While less than 5% of women survive the disease for 5 years if 
diagnosed at the most advanced stage (IV), when diagnosed early (at stage 1) 90% 
will survive. A successful screening programme would therefore be a highly valued 
public health care intervention.  
 
The primary aim of this paper is to draw on the clinical results arising from the 
mortality reduction seen in the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) to estimate a within trial period incremental cost-effectiveness ratio to 
assess the value to the UK National Health Service (NHS) covered population from 
the initiation of two screening scenarios as compared with a no screening (control) 
group in which no-screening for ovarian cancer was undertaken (Jacobs et al, 2016). 
The first screening programme was based on annual multimodal screening (MMS) 
which is based on detection of raised serum levels of CA125 using a risk of ovarian 
cancer algorithm (ROCA) to identify women who may have ovarian cancer (potential 
cases). The second programme relies on the identification of potential cases through 
annual transvaginal ultrasound screening (USS). UKCTOCS reported indicative 
findings that positive mortality benefit might well be gained from an ovarian cancer 
screening programme. This paper supplements the reported clinical results with 
estimates of the cost-effectiveness of the MMS and USS screening programmes 
compared separately to a no-screening arm based on individual patient level trial data.  
 
As well as presenting within trial incremental cost-effectiveness ratios (ICERs), we 
also present  incremental cost-effectiveness results for the MMS programme versus 
no screening which extrapolates findings past the end of the currently published 14-
year follow-up in UKCTOCS. This extrapolation helps to counter the long lead times 
required to establish the mortality benefits from an ovarian cancer screening 
programme. Given the uncertainties involved in extrapolation, we draw upon two 
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different modelling approaches. The first is founded upon direct predictions based on 
the underlying mortality rates revealed by the trial and associated predicted costs. The 
second uses a Markov model incorporating the UKCTOCS results to extrapolate costs 
and effects over a hypothetical population cohort. While necessarily adopting a 
different model structure, this latter approach has the additional advantage of allowing 
assessment of competing mortality risks and quality of adjusted life years (QALY).  
 
Methods 
Patients, setting and comparisons 
In UKCTOCS trial 202 638 women aged between 50-75 were recruited between 17th 
April 2001 and the 29th September 2005 through 13 UK National Health Service 
(NHS) Trusts. They were randomly allocated between 1st June 2001 and 21st October 
2005 to either annual multimodal screening (MMS: 50 640) using serum CA125 
interpreted through an algorithm (ROCA) with transvaginal ultrasound as a second 
line test or to annual transvaginal ultrasound screening (USS: 50 639 individuals) or 
to no-screening (101 359 individuals) (Jacobs et al, 2016). After exclusions relating to 
pre-existing ovarian cancer, or death/loss to follow-up between randomisation and 
initiation of screening, the total population of women analysed was 202 546, of which 
101 299 were in the no-screening arm, 50 624 were in the MMS arm and 50 623 were 
in the USS arm. Screening was completed at the end of 2011 with follow-up till the 
end of 2014.  
 
The primary outcome was ovarian cancer death confirmed by an independent 
outcomes review committee by the end of December 2014. Ovarian cancer was 
defined as malignant neoplasms of the ovary (ICD-10 C56), which included primary 
non-epithelial ovarian cancer, borderline epithelial ovarian cancer, and invasive 
epithelial ovarian cancer; malignant neoplasms of the fallopian tube (ICD-10 C57.0); 
and undesignated malignancies of the ovaries, fallopian tube or peritoneum. Primary 
peritoneal cancer as defined by WHO 2003 was not part of the primary outcome. The 
trial compared ovarian cancer deaths in MMS and USS versus no-screening groups. 
Survival time was estimated from the date of randomisation to the date of death due to 
the primary outcome or censoring, (where censoring included death from other causes 
or loss to follow-up). At end of study 649 (0.32%) women had died of ovarian cancer; 
347 (0.34%) in the no-screening arm, 148 (0.29%) in the MMS arm; and 154 (0.30%) 
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in the USS arm. The mortality reduction over the complete follow-up time of 14 years 
was 15% (95% CI -3 to 30; p=0.10) in the MMS arm and 11% (95% CI -7 to 27; 
p=0.21) in the USS arm. 
 
The cumulative hazards for the two screening arms began to separate after 7 years for 
the MMS versus no-screening group and 9 years for the USS versus no-screening 
group comparisons revealing a substantial delayed effect of screening on mortality. 
Analysis of this delayed effect showed that screening had a statistically significant 
impact on mortality when this lead time was accounted for. Over the later trial period, 
from 7-14 years, in the MMS screened group there was a statistically significant 
mortality reduction of 23% (95% CI 1 to 46). For the USS group the 7-14 year 
mortality impact was 21% (95% CI -2 to 42). At censorship, the no-screening group 
ovarian cancer mortality rate was continuing to rise linearly, whereas the MMS and 
USS group rates appeared to be plateauing (Jacobs et al, 2016) 
 
Form of evaluation and perspective 
In this analysis, we report an incremental cost-effectiveness analysis of the MMS and 
USS screening programmes separately comparing them to a no-screening arm over 
the period of the trial.  As USS is strictly dominated (is more costly and less effective 
than) by MMS, the USS versus control result is reported for information only for the 
within trial analysis. The analysis is based on individual patient level data collected 
during the trial and is assessed from the perspective of a national NHS screening 
programme. We therefore analyse only direct health service costs covering the 
programme costs of the MMS and USS screening and the subsequent treatment costs. 
 
The primary cost-effectiveness analysis therefore relates to assessment of the MMS 
and USS screening programmes compared to the control population who were not 
subject to screening within the trial follow-up period of 14 years. As there was a long-
lead time required to establish mortality benefit, as represented by the separation of 
cumulative mortality rates and within trial hazard rates only after 7 years across the 
screening arms and the control arm of UKCTOCS (Jacobs et al,2016; Figures 1,2,3), 
and given that USS was dominated by MMS we also present a secondary incremental 
cost-effectiveness ratio (ICER) for the MMS group alone compared to the no 
screening group estimated over a 25-year period through extrapolating cumulative 
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mortality and costs beyond the end of the trial follow-up period of 14 years. The 25-
year period was based on the median age (60.6; IQR 56,66) of women at 
randomisation and UK ONS Life Table data estimating life expectancy at this age to 
be approximately 25 years. Recognising the uncertainty associated with extrapolation 
we further undertake Markov modelling of a hypothetical population cohort, based on 
the UKCTOCS population, to extrapolate the ICER. The Markov model is based on a 
(“well”) population of 60-year-old females who transition through states of benign 
oophorectomy, early stage ovarian cancer, advanced ovarian cancer, death from 
ovarian cancer, and death from competing mortality. Data taken directly from 
UKCTOCS provided information on the states of benign oophorectomy, early stage 
ovarian cancer, advanced ovarian cancer and death from ovarian cancer, while ONS 
Life Tables provided the data on competing risks. 
 
Health outcome 
The effectiveness of the screening programme was based directly on the trial primary 
outcome of mortality due to ovarian cancer, which was converted to life-years gained 
(LYG) for the within trial analysis. . We used the Kaplan-Meier product limit 
estimates of time to death from ovarian cancer, which were reported in UKCTOCS 
(Jacobs et al, 2016), to calculate the average gain in life expectancy for the MMS and 
USS screening arms within the trial period as estimated by a calculated restricted 
mean. The MMS extrapolation, estimated through predicted mortality rates, also 
reports incremental cost per year of life gained from the screening programme versus 
no-screening. While the Markov model reports Quality Adjusted Life-Years (QALYs) 
through incorporating secondary data on QALY tariffs. Life-years and QALYs gained 
were discounted at the UK National Institute of Clinical Excellence (NICE) 
recommended rate of 1.5% per annum for public health interventions as well as at the 
general recommended rate of 3.5% per annum for health care treatment programmes 
(NICE, 2012; NICE, 2013).  
 
 
Resource use and cost  
For each patient within the trial all resource usage relative to screening was captured. 
For those referred for assessment due to screen findings, data related to clinic visits, 
additional imaging, blood tests, trial related surgery, all chemotherapy agents and the 
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number of cycles recorded for those treated for ovarian cancer and follow-up clinical 
assessment was captured through review of medical notes. We contacted treating 
clinicians irrespective of whether they were located in the NHS or private sector to 
obtain medical notes. The majority of the patients had treatment in the NHS with a 
small minority treated privately. Only one woman who had undergone trial surgery 
refused access to notes.  Once we mapped resource use, the 2013-2014 NHS tariff 
prices associated with relevant hospital episodes (in-patient, day case and out-patient), 
procedures, blood tests and clinics were attached to these visits (UK Dept. of Health, 
2014). The unit costs arising from treatment of ovarian cancer with chemotherapy 
agents were supplemented from a number of secondary sources, primarily reports 
from NICE (UK) and the British National Formulary prices (RICS, 2014). 
 
The only exception to the use of published unit costs was the unit cost of the CA125-
ROCA test used to predict the likelihood of ovarian cancer. This test is currently not 
available in the NHS. The cost a private health care sector CA125 test is 
approximately £85 (range 75-95), relative to the NHS cost of the CA125 test of £10. 
The cost of the ROCA as currently performed in the UK private health care sector is 
£150. The unit cost of the ROCA test in the NHS was therefore estimated through 
using a UK private health sector average 8.5 fold mark-up for CA125 over the NHS 
diagnostic test costs, with a returned estimate of £17 for the combined CA125-ROCA 
test if it were to be performed in the NHS. An estimate of £20 was therefore used in 
the base-case analysis and subjected to extensive sensitivity analysis to account for 
the gross uncertainty surrounding this estimated NHS value. The direct screening 
costs per patient over the trial period represent approximately 50% of the total 
individual per patient costs for those in the screening arms. 
 
All unit costs are reported in Table 1. These unit costs, given in 2013/14 prices (£ 
sterling), were combined with individual patient specific resource volumes to obtain a 
total cost per patient for each type of resource and year. These were aggregated to 
provide a total cost per patient over the entire period of the trial in each arm, which 
was used to estimate the mean cost per patient screening arm. 
 
Given the presence of right censoring in the cost data, the approach recommended by 
Lin et al (1997) was used to adjust the within trial cost estimates for censoring. As 
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individual cost history information at intermediate points in time was available, the 
chosen estimator proposed by Lin et al partitions the entire study period into discrete 
time intervals of one year in our case and makes use of individual cost histories to 
derive an estimate of average cost within each interval of the partition. The final 
estimate of average cost over the whole period of analysis is then based on weighting 
each interval cost estimate by the respective Kaplan-Meier probability of survival to 
the start of the interval and aggregating these interval cost estimates across the entire 
analysis period.  In-this manner an estimate of mean total cost per patient adjusted for 
censoring was derived for each of the trial arms.  
 
Combining the above cost and effect estimates to produce differences in the average 
costs relative to differences in the average effects results in an incremental cost-
effectiveness ratio statistic for each comparison. To address the uncertainty around 
these values Fieller’s method for estimating the confidence intervals of ratios was 
used (Fieller, 1954). 
 
 
Extrapolation  
Given the age of the trial population at randomisation (median 60.6; IQR 56,66) and 
that the evaluation assesses the effects of a screening programme, extrapolating the 
within trial results out to 25 years was considered appropriate, as this is the life 
expectancy of a 60-year-old female in the UK, in order to capture the delayed effects 
of the programme while accounting for its future costs.  
 
Given the uncertainty associated with extrapolation two approaches were adopted. 
The first is based on predicting future mortality and cost from the trial population data 
directly. The second, is based on Markov modelling of a hypothetical cohort that used 
the within trial data to estimate transition probabilities across different states. 
 
For the first extrapolation of effect, the Royston-Parmar (2002) parametric estimates 
of time to ovarian cancer death, which reported results consistent with the Kaplan-
Meier estimates over the trial period (Jacobs et al, 2016), were used to predict LYG 
beyond the end of the trial. This allowed better representation of the full gain in 
improved mortality from ovarian cancer witnessed as screening was affected by 
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considerable lead time. For the extrapolation the Royston-Parmar estimates were 
based on the specification shown to give the best fit to the trial data through 
application of the Akaike Information Criterion (AIC) of model selection (Royston 
and Parmar, 2002). No account was taken of competing risks given that there was no 
(statistical) difference observed in these risks across the groups within the trial. 
Analysis was therefore based purely on the trial estimated ovarian mortality rates. 
Extrapolated LYGs were discounted, at both 1.5% and 3.5%.  
 
To estimate the relevant costs over the period of the extrapolation the method 
suggested by Etzioni et al (1999) was adopted. Here the extrapolation period is 
disaggregated into years and for each year the average cost was assumed to consist of 
two components. The first component gives an estimate of average cost for those who 
are expected to survive the year based on the within trial annual observed costs of the 
survivors and weighted by a parametrically estimated probability of surviving the 
year. The second component gives an estimate of average cost for those who are 
expected to die in the year based on the within trial annual observed costs of those 
who die and weighted by the respective estimate of the probability of dying in the 
year. To derive the parametric estimates of survival for each year of the extrapolation 
period the Royston-Parmar estimates were used.  
 
Given the approach by Etzioni et al (1999) adopted here, as detailed above, future 
costs are assumed to follow a similar pattern to that observed within the trial, that is, 
they assume that patients will continue to receive screening, testing and any necessary 
treatment beyond the end of the trial and up to the end of the extrapolation period. 
 
The second method of extrapolation was based on a Markov model, with a 1-year 
cycle, as given in Figure 1 which identifies the transition and terminal states. All data, 
apart from that on competing risk and quality of life values were taken from the 
UKCTOCS. The transitions from well to benign oophorectomy, early stage ovarian 
cancer, late stage ovarian cancer and death from ovarian cancer were based on 
UKCTOCS within trial Kaplan-Meier estimates of annual hazards to these end-points, 
which were converted into annual transition probabilities. The quality of life (QoL) 
data were taken from Edwards, Barton, Thurgar et al, (2015) who reviewed 187 
papers reporting QoL data relating to ovarian cancer, of which 27 provided data 
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suitable for use in economic evaluations. While their concern was with advanced 
recurrent and refractory ovarian cancer, the study reported QoL tariffs for stable and 
progressive disease, estimated at 0.718 and 0.649 respectively. These values were 
based on a sample population of over 600 patients and were generally representative 
of values used for similar states in other studies. We take these values to proxy the 
QoL tariffs for early stage ovarian cancer (0.718) and advanced ovarian cancer 
(0.649) within the Markov model. The competing risk of mortality was based on UK 
ONS Life Tables of annual mortality rates for 60-year-old women, which when 
combined with the ovarian cancer mortality rates allowed the cohort to be followed 
until all had reached death.  
 
For the Markov model costs were attributed to each state on the following basis. The 
screening cost was taken as CA125 plus ROCA at £20, plus phlebotomy at £3 and a 
specialist gynaecological out-patient visit cost of £109. The cost of benign 
oophorectomy was £2,275 plus an additional out-patient follow-up visit of £139. 
Early and advanced ovarian cancer was recorded for each of the UKCTOCS 
participants.  In the early ovarian cancer state which includes borderline and non-
epithelial ovarian cancer, based on the trial findings an average of 49% of individuals 
received surgery alone and 51% received surgery and chemotherapy, giving a 
weighted average cost of £3,422 including all surgeries, chemotherapies and out-
patient follow-ups; while the advanced ovarian cancer state, where 29% of 
UKCTOCS individuals had chemotherapy, 8% had surgery alone and 63% had 
surgery and chemotherapy had a weighted average cost, estimated on a similar basis 
of £5,666. 
 
Sensitivity analysis 
While the majority of costs reflect NHS treatment costs, as noted above the combined 
CA125-ROCA unit cost, which is central to the programme cost of the MMS arm, is 
at present unknown within the NHS as the ROCA is not routinely performed in the 
public sector. The £20 base-case CA125-ROCA cost was estimated from the known 
UK private hospital sector cost of the CA125 test and ROCA adjusted through the 
estimated private-to-public hospital sector mark-up. Given the uncertainty over this 
unit cost, univariate sensitivity analysis was undertaken with the CA125-ROCA unit 
cost assessed at £15, £30, £40 and £50 per test respectively to assess the impact of 
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this critical value on the ICER estimates. This sensitivity analysis was applied to both 
the within trial and the predicted extrapolation analysis. The Markov model applied 
probabilistic sensitivity analysis to a distribution of CA125-ROCA costs ranging from 
£15 to £50 using a uniform distribution. Only the control versus MMS ICERs are 
reported for the within trial sensitivity analysis, the predicted extrapolations and the 
Markov modelling as the trial USS strategy is completely dominated by the MMS 
strategy. 
 
 
 
 
Results 
We report the ICERs for the within trial comparisons of the MMS group versus no-
screening group and the USS group versus no-screening group, as well as for the 
MMS versus control extrapolation beyond the trial follow-up period of 14 years out to 
25 years, the latter chosen as reflecting a reasonable aggregate survival time when 
account is taken of competing risks for the trial population. Results are reported with 
discount rates at 1.5% applied to the effects (LYG and QALYs) and to the costs, as 
the main results reflect the view that screening is considered a public health 
intervention, and with LYG and QALYs discounted at 3.5%. We report the within 
trial results as mean estimates accompanied by their variance estimators, with ICERs 
reported together with their 95% confidence intervals using Fieller’s (1954) method. 
 
The mean time to death, defined by the primary outcome measure death from ovarian 
cancer, is reported in Table 2 by screening arm. The results reproduce those reported 
in the published UKCTOCS analysis and supplement these by the discounted 
estimates of time to death from ovarian cancer using discount rates of 1.5% and 3.5%. 
As can be seen, and consistent with the trial results, the Kaplan-Meier estimated time 
to death from ovarian cancer in the control arm is 13.5574 years undiscounted, 
12.36565 years when discounted at 1.5%, (11.01755 years when discounted at 3.5%). 
For the MMS treatment arm the respective times to death from ovarian cancer are 
13.5607 years for undiscounted estimates, 12.3685 years when discounted at 1.5%, 
(11.01979 years discounted at 3.5%), while for the USS arm they are 13.5597 years 
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(undiscounted), 12.3676 years when discounted at 1.5%, (11.0191 years when 
discounted at 3.5%). 
 
Table 3 reports the mean cost per patient over the duration of the study by programme 
allocation, discounted at 1.5% and 3.5% per year, adjusted for censoring. As shown, 
and not surprisingly, the no-screening arm exhibited extremely low costs over the trial 
period; £135 discounted at 1.5% (£122 discounted at 3.5%) when adjusted for 
censoring. These costs are essentially a “do-nothing” intervention plus treatment costs 
arising from the small number, relative to the total population, of individuals in this 
arm presenting with ovarian cancer at some point within the trial. The MMS group 
had a mean (adjusted for censoring) cost of £391 when discounted at 1.5%, (£360 
discounted at 3.5%) during the trial period. The USS screening arm had a much more 
expensive mean (adjusted for censoring) cost of £1,342 when discounted at 1.5%, 
(£1,259 discounted at 3.5%) during the trial period. In all cases these mean costs 
represent the screening cost plus any treatment costs for detected ovarian cancer 
averaged or the relevant population. 
 
These cost and effect estimates formed the basis for the estimation of the within trial 
incremental cost-effectiveness ratios (ICERs) which are reported in Table 4. These 
ICERs are calculated as the incremental cost per life year gained (LYG) for the MMS 
arm versus no-screening arm and the USS arm versus no-screening arm. In each case, 
both costs and LYG are discounted at 1.5% as well as 3.5%. The ICERs account for 
censoring in both cost and effect estimates. As estimated the USS versus no-screening 
ICER is extremely high, calculated to be £625,801 (95% CI £620,451, £631,245) per 
LYG at a 1.5% discount rate and £748,315 (95% CI £741,446, £755,312) per LYG at 
a 3.5% discount rate. These high values for the ICERs are due to a number of factors. 
First, the small overall benefit derived in terms of time to death from ovarian cancer 
from the within trial USS screening programme is a reflection of the long lead-time, 
of around 7 years, to the associated mortality gain from screening. Coupled with the 
effect of discounting and the impact of the ICER being a calculated ratio, this gives 
rise to the high USS ICER estimate. 
 
The estimated within trial cost per LYG arising from the MMS programme is lower at 
£91,452 (95% CI £90,909, £92,001) per LYG when discounted at 1.5%, and £106,497 
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(95% CI £105,840, £107,162) per LYG when discounted at 3.5% but remains 
relatively high for similar reasons to those outlined for the USS versus no-screening 
arm. Following these results and in accordance with the approach adopted in the 
clinical trial mortality analysis (Jacobs et al, 2016), the subsequent discussion of the 
cost-effectiveness of the screening programme focuses on the comparison of the 
MMS programme versus no-screening arms, given the dominance of MMS over USS. 
 
Given the long lead time experienced to derive mortality benefit and given that the 
UKCTOCs trial shows widely divergent hazard rates across the control and MMS 
population after 7-years (Jacobs et al, 2016), we extend the analysis to include an 
extrapolation of the ICER out to 25 years. This extrapolated period of an additional 11 
years is chosen as a reasonable length over which average life expectancy in this age 
group, given competing risks, might be extended; ONS estimates average life 
expectancy of a 60-year-old female to be 25.22 years. Figure 2 shows the resultant 
extrapolated cumulative survival curves for the MMS and no-screening arms, which 
we believe to be conservative estimates of the health gain from screening given the 
increasingly divergent hazard rates across the MMS and no-screening groups seen in 
Figure 3 of the trial analysis (Jacobs et al, 2016). The extrapolated ICERs for the 
MMS versus no-screening population, discounted at 1.5% and 3.5% are also reported 
in Table 4 alongside the main within trial results. The reported ICERs, reflect both 
increasing treatment cost differences over time but, more importantly, increasing 
LYG as the screening programme matures and are estimated at £30,033 per LYG 
when a discount rate of 1.5% is applied to both costs and effects and at £35,544 per 
LYG when discounted at 3.5%. 
 
The results of the univariate sensitivity analysis was limited to the ICER for the MMS 
versus no screening, and where the CA125-ROCA unit cost were assumed to be £15, 
£30, £40 and £50 per test respectively are reported in Table 5. These values were 
deemed representative of the most plausible range of costs that could be negotiated 
through the NHS for the CA125-ROCA test. A value greater than £50 for this test was 
not considered, as the resultant ICER estimate relating to the within trial analysis 
reaches £173,258 per LYG and even in the extrapolation period of analysis (for the 
MMS versus no-screening comparison) the ICER is £56,962 per LYG. Further 
increases in screening cost would merely push these ICERs higher. 
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In the within trial sensitivity analysis the estimated ICERs for the MSS versus no-
screening comparisons remain high.  The average cost per LYG ranges from £77,818 
per LYG (Table 5; confidence intervals also reported) when the CA125-ROCA cost 
was £15, to £173,258 per LYG when the CA125-ROCA test costs was increased to 
£50 and outcomes are discounted at 1.5% (if a discount rate of 3.5% is applied the 
ICER range is £90,549 per LYG with the CA125-ROCA test cost £15, to £202,189 
per LYG with CA125-ROCA test cost £50).  
 
Again, these relatively high within trial ICERs reflect the fact that there is a long-lead 
time associated with the accrual of the mortality benefits gained from screening. 
Accounting for these long-lead times through extrapolating the costs and mortality 
benefits over a 25-year period the ICERs fall considerably. 
 
In the base-case predicted extrapolation analysis, using the Royston-Parmar 
predictions of mortality rates and the Etzioni et al (1999) method for extrapolating 
costs, with the CA125-ROCA test cost estimated at £20 and discounting at 1.5%, the 
incremental cost per LYG for the MMS intervention was calculated to be £30,033 per 
LYG compared to no screening (£35,544 per LYG discounting at 3.5%). If the 
CA125-ROCA test cost falls to £15 the ICER becomes £25,545 per LYG at a 1.5% 
discount rate (£30,220 per LYG discounting at 3.5%). Over the total 25-year period of 
analysis (within trial and extrapolation) at a 1.5% per annum discount rate the ICER 
rises to £39,009 per LYG with the CA125-ROCA test at £30; £47,986 per LYG with 
the CA125-ROCA at £40; and £56,962 per LYG with the CA125-ROCA test cost at 
£50.  
 
For the Markov model the extrapolated LYG are estimated to be 0.039, when 
discounted at 1.5% and although not directly comparable as the model forces 
individuals through transition states, are greater than the 0.014 LYG estimated 
through the predictive extrapolation. Given that the Markov model incorporates 
competing mortality risk the direction of difference is correct. The extrapolated 
QALYs in the Markov model are estimated to be 0.0581, as based on the average 
effect size seen during the UKCTOCS holding across the extrapolation.  The base-
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case analysis in the Markov model comparing the MMS to no screening estimates a 
ICER, using QALYs as the outcome, to be £46,922 per QALY gained discounting at 
1.5% (£54,267 per QALY when both costs and effects are discounted at 3.5%). The 
probabilistic sensitivity analysis, applying a uniform distribution to a CA125-ROCA 
cost which lies between £10 and £50, returns a minimum ICER of £45,030 per QALY 
and a maximum value of £61,134 per QALY. 
 
Discussion 
We report on cost effectiveness of screening using within trial data from one of the 
world’s largest multicentre randomised controlled trials involving 202 546 women,  
673 765(median of 8 per women in screen arms) annual screens and 2.2 million 
women-years of follow-up. (Jacobs et al, 2016). Our analysis suggests that, after 
accounting for the lead-time required to establish full mortality benefits, a national 
OCS programme based on the MMS strategy when extrapolated out to lifetime could 
approach the current NICE thresholds for cost-effectiveness (£30,033 per LYG on 
predictive extrapolation and £46,922 per QALY on Markov modelling) as compared 
to the within trial ICER estimates (£91,452 - £77,818 per LYG.). This suggests that 
MMS could be recommended on economic grounds if a definitive mortality benefit of 
20% is confirmed on follow-up of the UKCTOCS cohort. 
 
Data on cost-effectiveness of screening for ovarian cancer is limited to the small 
number of cost-effectiveness studies.  The modelling undertaken is limited and based 
on various assumptions concerning the reliability of screening regimes, with few 
taking account of quality of life considerations. Edwards et al (2015) and Sfakianos 
and Havrileskey (2011) have provided comprehensive reviews of this area, detailing 
that none have been based on long-term trials. As a result, the evidence base for the 
cost-effectiveness of screening for ovarian cancer is, to this point, weak. 
 
This analysis is the first to estimate incremental cost-effectiveness ratios based 
directly on within trial (UKCTOCS) individual patient data. Not surprisingly given 
the impact of the long lead time taken to establish the health benefits, the estimated 
within trial ICERs are relatively high. The most favourable within trial ratio relating 
to the comparison of the MMS arm versus no-screening is calculated to be £91,452 
per LYG accounting for censoring in both cost and mortality estimates and applying 
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the NICE public health programme discount rate of 1.5% per annum. It is important 
to note that this relatively high cost-effectiveness ratio is not a result of the average 
cost per patient being large over the trial period, but a direct consequence of the trial 
not being long enough to adequately reflect the full mortality benefits likely to be 
gained from the MMS programme. 
 
As a result, the extrapolation of the within trial results become critical. Extrapolation 
highlights the problems of model uncertainty, as well as the general issues 
surrounding prediction. We have therefore resorted to two extrapolations; one based 
on predictions of within trial mortality rates and treatment costs beyond the trial 
period and one based on the development of a Markov model founded on data from 
the UKCTOCS trial applied to a hypothetical cohort moved through a number of 
health states. 
 
One advantage of the Markov modelling is that it can incorporate QoL data gained 
from outside the trial. While extensive quality of life data were collected during the 
trial, these were related to screening or profile data and are not readily convertible to 
the tariff values required to calculate Quality Adjusted Life Year (QALY) gains 
(Barrett et al, 2014). The calculation of QALYs would have, for example, allowed 
precise quantitative estimation of the impact that screening complications and false-
positive results had on the quality of life of the women involved. Such an impact, we 
believe would have been small as less than 1% of the women in either the USS or 
MMS screening arms experienced screen complications, all of which were mild such 
a bruising or discomfort during scanning/blood test, while the number of false-
positive surgeries performed were 50 per 10,000 screens in the USS group and 14 per 
10,000 screens in the MMS group. The costs of these false positive surgeries are 
captured in all the reported analysis, but it is only in the Markov analysis that QALY 
estimates were provided. 
 
The predictive modelling of the ICER provides an estimate for the MMS programme 
relative to the no-screening population extrapolated out to a 25-year period which 
falls dramatically to £30,033 per LYG when a discount rate of 1.5% is applied 
(£35,544 per LYG when a discount rate of 3.5% is applied). While for the Markov 
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model the extrapolated cost per QALY, in an analysis that also incorporates 
competing mortality risks, is estimated to be £46,922 per QALY.  
Both provide indicative evidence that, if using the conventional NICE threshold of 
£20,000 per QALY to £30,000 per QALY to deem interventions cost-effective, a 
screening strategy based on the MMS programme fast approaches becoming cost-
effective when compared to the within trial analysis when the programme is 
lengthened using within trial mortality benefits as the basis of extrapolation. 
 
The long lead-time associated with establishing mortality benefit from ovarian cancer 
screening has meant that the full benefits to be realised from such a programme have 
not been established authoritatively. This is further complicated by the presence of 
pre-existing cancers within the trial population at the first screen. Indeed, in a pre-
specified secondary analysis that excluded prevalent cases from the analysis 
population a statistically significant 28% mortality reduction was shown in the MMS 
arm after 7 years of the trial (Jacobs et al, 2016). If this increased mortality gain were 
to convert into a larger gain in time to survival for the MMS arm, this would greatly 
improve the cost-effectiveness estimates given that we are using extremely low values 
in the denominator of the calculated ICERs. Given that the trial population is a mixed 
cohort of prevalence and incidence cases more complex modelling than undertaken 
here would be required to fully establish this case. 
 
The findings are not only highly dependent on the average effect size of the mortality 
reduction associated with screening, but also the cost of the CA125-ROCA test, 
assuming this test is adopted by the NHS. The base-case analysis of the predictive 
extrapolation model and of the Markov model both use a CA125-ROCA cost of £20. 
Even this seems relatively high as the current average NHS cost for histopathology 
and histology tests within the NHS are £10. Moreover, if as is possible given the 
continuing divergence of the hazard rates for the no-screening and MMS arms at 
censorship for mortality analysis, the screening effect benefit continues to grow, the 
ICER will continue to approach the NICE threshold. We have been deliberately 
conservative, given the uncertainties associated with extrapolation and prediction and 
the difficulties of estimating the cost to the NHS of the CA125-ROCA test. 
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In conclusion, the results of the extrapolation over lifetime suggest that a public 
health programme of screening for ovarian cancer could become cost-effective within 
an NHS setting if the mortality benefit from screening continues to increase over 
time. Any definitive conclusion as to whether MMS could be recommended on 
economic grounds would depend on the confirmation and size of the mortality benefit 
at the end of ongoing follow-up of the UKCTOCS cohort. 
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The cost-effectiveness of screening for ovarian cancer: results from the UK 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 
 
Figures and Tables 
 
 
Table 1. Unit costs applied to the Incremental Cost-effectiveness Ratios 
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Table 2. Mean time to primary death by treatment group within the trial period 
 
 Control  Multimodal  Ultrasound  
 N=101299 Mean (s.e.) N=50624 Mean (s.e.) N=50623 Mean 
(s.e.) 
Kaplan-Meier 
(undiscounted) 
 13.55736 
(0.0014) 
 13.56069 
(0.0019) 
 13.55967 
(0.0019) 
Kaplan-Meier 
(discounted at 
1.5%) 
 12.36565 
(0.0012) 
 12.36845 
(0.0017) 
 12.36758 
(0.0017) 
Kaplan-Meier 
(discounted at 
3.5%) 
 11.01755 
(0.0011) 
 11.01979 
(0.0014) 
 11.01907 
(0.0014) 
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Table 3. Mean cost per patient over the trial period (ROCA=£20) 
 Control  Multimodal  Ultrasound  
 Mean* Variance* Mean*  Variance* Mean*  Variance* 
Adjusted for 
censoring, 
undiscounted 
£146 £40 £416 £56 £1,412 £77 
Adjusted for 
censoring, 
discounted at 
1.5% 
£135 £30 £391 £47 £1,342 £66 
Adjusted for 
censoring, 
discounted at 
3.5% 
£122 £22 £360 £38 £1,259 £56 
*Means and variances were estimated using the Lin et al (1997) estimator  
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Table 4. Incremental cost-effectiveness ratios for the MMS versus control and 
USS versus control comparisons within the trial period (ROCA=£20) 
 Multimodal 
versus Control 
  Ultrasound 
versus Control 
  
 Cost difference Effect 
difference 
ICER 
(95% 
confidence 
interval) 
Cost difference Effect 
difference 
ICER 
( 95% 
confidence 
interval) 
Discounted at 
1.5% and both 
costs and 
effects 
adjusted for 
censoring 
£256 0.0028 £91,452 per 
LYG 
(£90,909,  
£92,001) 
£1,208 0.00193 £625,801 per 
LYG 
(£620,451, 
£631,245) 
Discounted at 
3.5% and both 
costs and 
effects 
adjusted for 
censoring 
£239 0.00224 £106,497 per 
LYG 
(£105,840, 
£107,162) 
£1,137 0.00152 £748,315 per 
LYG 
(£741,446, 
£755,312) 
Results for Multimodal versus Control ICER Extrapolated to 25 years 
Discounted at 
1.5% 
£427 0.01421 £30,033 per 
LYG 
   
Discounted at 
3.5% 
£358 0.01008 £35,544 per 
LYG 
   
Note: ICER values differ from straight division of Cost difference by Effect difference due to rounding 
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Table 5. Incremental cost-effectiveness ratios for the MMS versus control and 
USS versus control comparisons within the trial period (ROCA=£15) 
 Multimodal 
versus Control 
  Ultrasound 
versus Control 
  
 Cost difference Effect 
difference 
ICER 
(95% 
confidence 
interval) 
Cost difference Effect 
difference 
ICER 
( 95% 
confidence 
interval) 
Discounted at 
1.5% 
£218 0.0028 £77,818 per 
LYG 
(£77356,  
£78285) 
£1,207 0.00193 £625,300 per 
LYG 
(£619954, 
£630740) 
Discounted at 
3.5%  
£203 0.00224 £90,549 per 
LYG 
(£89990, 
£91115) 
£1,137 0.00152 £747,717 per 
LYG 
(£740854, 
£754708) 
Results for Multimodal versus Control ICER Extrapolated to 25 years 
(ROCA=£15) 
Discounted at 
1.5% 
£363 0.01421 £25,545 per 
LYG 
   
Discounted at 
3.5% 
£305 0.01008 £30,220 per 
LYG 
   
 (ROCA=£30) 
Discounted at 
1.5%  
£332 0.0028 £118,721 per 
LYG 
(£118017, 
£119432) 
£1,210 0.00193 £626,802 per 
LYG 
(621443, 
£632255) 
Discounted at 
3.5%  
£310 0.00224 £138,395 per 
LYG 
(£137542, 
£139258) 
£1,139 0.00152 £749,510 per 
LYG 
(£742630, 
£756518) 
Results for Multimodal versus Control ICER Extrapolated to 25 
years(ROCA=£30) 
Discounted at 
1.5% 
£554 0.01421 £39,009 per 
LYG 
   
Discounted at 
3.5% 
£466 0.01008 £46,194 per 
LYG 
   
 (ROCA=£40) 
Discounted at 
1.5%  
£409 0.0028 £145,989 per 
LYG 
(£145,125,  
£146,864) 
£1,212 0.00193 £627,804 per 
LYG 
(£622,436, 
£633,265) 
Discounted at 
3.5%  
£381 0.00224 £170,292 per 
LYG 
(£169,243, 
£171,354) 
£1,141 0.00152 £750,705 per 
LYG 
(£743,814, 
£757,724) 
Results for Multimodal versus Control ICER Extrapolated to 25 
years(ROCA=£40) 
Discounted at 
1.5% 
£682 0.01421 £47,986 per 
LYG 
   
Discounted at 
3.5% 
£573 0.01008 £56,843 per 
LYG 
   
(ROCA=£50) 
Discounted at 
1.5%  
£485 0.0028 £173,258 per 
LYG 
(£172,233,  
£174,296) 
£1,214 0.00193 £628,805 per 
LYG 
(£623,428, 
£634,275) 
Discounted at 
3.5%  
£453 0.00224 £202,189 per 
LYG 
(£200,945, 
£203,449) 
£1,143 0.00152 £751,900 per 
LYG 
(£744,998, 
£758,930) 
Results for Multimodal versus Control ICER Extrapolated to 25 
years(ROCA=£50) 
Discounted at 
1.5% 
£809 0.01421 £56,962 per 
LYG 
   
Discounted at 
3.5% 
£680 0.01008 £67,492 per 
LYG 
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Note: ICER values differ from straight division of Cost difference by Effect difference due to roundings 
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Figure 1 Markov Transition States 
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Figure 2. Predicted cumulative survival probability from ovarian cancer over the 
extrapolation period for the MMS versus no-screening comparison 
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